AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23720367 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 201
Study 23720367 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination at 10 to 11 months
Number of subjects: 201
Study 23720367 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal CD4 T-cell count <200 cells/μl
Number of subjects: 201
Study 23720367 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted infants
Number of subjects: 201
Study 23720367 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower infant height-for-age z-scores
Number of subjects: 201
Study 20954671 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-midvastus approach (group A)
Number of subjects: 134
Study 20954671 — intervention group
Group type: COMPARATOR
Intervention: Mini-medial parapatellar approach (group B)
Number of subjects: 134
Study 18472087 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralisation solution with 1 ppm fluoride for five days
Number of subjects: 45
Study 18472087 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralisation solution with 5 ppm fluoride for five days
Number of subjects: 45
Study 18472087 — intervention group
Group type: COMPARATOR
Intervention: Control group (no demineralisation solution)
Number of subjects: 45
Study 19299808 — intervention group
Group type: COMPARATOR
Intervention: EDA group (15 patients)
Number of subjects: 20
Study 19299808 — intervention group
Group type: COMPARATOR
Intervention: EDA-NE group (5 patients)
Number of subjects: 20
Study 19299808 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients)
Number of subjects: 20
Study 15177597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpenetrating deep sclerectomy with T‐flux implant
Number of subjects: 34
Study 15177597 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscocanalostomy
Number of subjects: 34
Study 15177597 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 34
Study 11561335 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making aid (manual and audiocassette describing a six-step approach to making a decision about HRT)
Number of subjects: 0
Study 11561335 — intervention group
Group type: COMPARATOR
Intervention: Information document from the Society of Obstetricians and Gynaecologists of Canada (SOGC)
Number of subjects: 0
Study 9621483 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI + DEX (1,000 mg/m2 i.v.)
Number of subjects: 95
Study 9621483 — intervention group
Group type: COMPARATOR
Intervention: EPI (160 mg/m2 i.v. every 3 weeks)
Number of subjects: 95
Study 7842365 — intervention group
Group type: EXPERIMENTAL
Intervention: KW 4679 (2.5, 5, or 10 mg b.i.d.)
Number of subjects: 15
Study 7842365 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg b.i.d.)
Number of subjects: 15
Study 7842365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7842365 — intervention group
Group type: EXPERIMENTAL
Intervention: KW 4679 (all doses)
Number of subjects: 15
Study 3279968 — intervention group
Group type: COMPARATOR
Intervention: Acipimox 750 mg/day for 60 days
Number of subjects: 17
Study 3279968 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 750 mg/day for first 6 months, then 1200 mg/day for last 3 months
Number of subjects: 17
Study 30673687 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise prescription
Number of subjects: 39
Study 30673687 — intervention group
Group type: COMPARATOR
Intervention: Standardized exercise prescription
Number of subjects: 39
Study 26775560 — intervention group
Group type: EXPERIMENTAL
Intervention: LNS-LQ/Cash
Number of subjects: 2586
Study 26775560 — intervention group
Group type: COMPARATOR
Intervention: LNS-MQ/Cash
Number of subjects: 2586
Study 25738348 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month loading group (group 1)
Number of subjects: 36
Study 25738348 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month loading group (group 2)
Number of subjects: 36
Study 24921223 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexTouch 100 (FT100)
Number of subjects: 128
Study 24921223 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexTouch 200 (FT200)
Number of subjects: 128
Study 24921223 — intervention group
Group type: COMPARATOR
Intervention: SoloSTAR
Number of subjects: 128
Study 21178179 — intervention group
Group type: EXPERIMENTAL
Intervention: Late RES ewes (60% of NRC recommendations)
Number of subjects: 64
Study 21178179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ewes fed ASe (3.05 μg/kg of BW)
Number of subjects: 64
Study 21178179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Se treatment and late gestation nutritional level
Number of subjects: 64
Study 19500346 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care program consisting of Watchful waiting, Guided self-help, Problem Solving Treatment, Medication and/or specialized mental health care
Number of subjects: 0
Study 19500346 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study 17548729 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP testing
Number of subjects: 500
Study 14765861 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous sulphate for six weeks
Number of subjects: 72
Study 14765861 — intervention group
Group type: COMPARATOR
Intervention: Placebo for six weeks
Number of subjects: 72
Study 11739066 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (400 mg/day)
Number of subjects: 21
Study 10436966 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E)
Number of subjects: 90
Study 10436966 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (M)
Number of subjects: 90
Study 10436966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (N)
Number of subjects: 90
Study 7935703 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethyl methacrylate membrane
Number of subjects: 72
Study 7935703 — intervention group
Group type: COMPARATOR
Intervention: Cuprophane membrane
Number of subjects: 72
Study 7935703 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethyl methacrylate membrane (nonoliguric acute renal failure)
Number of subjects: 72
Study 7935703 — intervention group
Group type: COMPARATOR
Intervention: Cuprophane membrane (nonoliguric acute renal failure)
Number of subjects: 72
Study 3284549 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrinogenation therapy
Number of subjects: 162
Study 3284549 — intervention group
Group type: COMPARATOR
Intervention: Steroid therapy
Number of subjects: 162
Study 30463524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone reminders
Number of subjects: 662
Study 30463524 — intervention group
Group type: COMPARATOR
Intervention: Physical contact tracing reminders
Number of subjects: 662
Study 26658775 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback on safety checklist compliance and efficiency metrics via display boards and text messages
Number of subjects: 1886
Study 26658775 — intervention group
Group type: COMPARATOR
Intervention: No feedback on safety checklist compliance and efficiency metrics
Number of subjects: 1886
Study 25171799 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath MAC
Number of subjects: 39
Study 22050040 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate (BT) 0.5% once daily
Number of subjects: 391
Study 22050040 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine tartrate (BT) 0.18% once daily
Number of subjects: 391
Study 22050040 — intervention group
Group type: COMPARATOR
Intervention: Vehicle once daily
Number of subjects: 391
Study 22050040 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine tartrate (BT) 0.18% twice daily
Number of subjects: 391
Study 22050040 — intervention group
Group type: COMPARATOR
Intervention: Vehicle twice daily
Number of subjects: 391
Study 22050040 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine tartrate (BT) 0.07%
Number of subjects: 391
Study 22050040 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine tartrate (BT) 0.18%
Number of subjects: 391
Study 22050040 — intervention group
Group type: COMPARATOR
Intervention: Single application of BT 0.5%
Number of subjects: 391
Study 20738023 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive tilting using 'Lojer 1445YH'
Number of subjects: 36
Study 20738023 — intervention group
Group type: COMPARATOR
Intervention: Functional bed position change (Control)
Number of subjects: 36
Study 18279480 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial agents RCTs
Number of subjects: 70
Study 16321130 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL-deficient knees
Number of subjects: 23
Study 16321130 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation of tibiofemoral contact pattern
Number of subjects: 23
Study 16321130 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since injury
Number of subjects: 23
Study 11912359 — intervention group
Group type: EXPERIMENTAL
Intervention: brimonidine-Purite 0.15%
Number of subjects: 1147
Study 11912359 — intervention group
Group type: EXPERIMENTAL
Intervention: brimonidine-Purite 0.2%
Number of subjects: 1147
Study 11912359 — intervention group
Group type: COMPARATOR
Intervention: brimonidine 0.2%
Number of subjects: 1147
Study 10220833 — intervention group
Group type: EXPERIMENTAL
Intervention: No medication or nonsteroidal antirheumatic drugs
Number of subjects: 20
Study 10220833 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids (in group II)
Number of subjects: 20
Study 10220833 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group III)
Number of subjects: 20
Study 8935108 — intervention group
Group type: COMPARATOR
Intervention: Acid etching of enamel alone for fragment bonding (n = 146)
Number of subjects: 334
Study 8935108 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enamel etching and dentinal bonding (n = 188)
Number of subjects: 334
Study 2696710 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac eyedrops
Number of subjects: 179
Study 2696710 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 179
Study 12675 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable combination of local anaesthetic (Xylestesin) and beta-receptor-blocker (Betadrenol)
Number of subjects: 30
Study 29237134 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational liquid nutritional formula (1g gamma-linolenic acid, 750μg iodine, 70μg selenium)
Number of subjects: 188
Study 29237134 — intervention group
Group type: COMPARATOR
Intervention: Control formula (without GLA, iodine, and selenium)
Number of subjects: 188
Study 29237134 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational liquid nutritional formula
Number of subjects: 188
Study 29237134 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 188
Study 27732968 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (standard dose and schedule)
Number of subjects: 213
Study 27732968 — intervention group
Group type: EXPERIMENTAL
Intervention: SBF2 variants
Number of subjects: 213
Study 24609851 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-engaged approaches including colearning opportunities, participatory procedures for community-academic involvement, and community and clinical capacity building.
Number of subjects: 0
Study 24609851 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 22816732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose statin therapy
Number of subjects: 91
Study 22816732 — intervention group
Group type: COMPARATOR
Intervention: Control (normocholesterolemic subjects)
Number of subjects: 91
Study 21197853 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual microgravity (AM)
Number of subjects: 5
Study 21197853 — intervention group
Group type: COMPARATOR
Intervention: Simulated microgravity (SM)
Number of subjects: 5
Study 18956981 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher religiosity scores
Number of subjects: 0
Study 16184071 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CrPic) 600 mug/day
Number of subjects: 113
Study 16184071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 16184071 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CrPic) in patients with high carbohydrate craving
Number of subjects: 113
Study 16184071 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with high carbohydrate craving
Number of subjects: 113
Study 12519653 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg arecoline
Number of subjects: 23
Study 12519653 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg arecoline
Number of subjects: 23
Study 12519653 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg arecoline
Number of subjects: 23
Study 12519653 — intervention group
Group type: COMPARATOR
Intervention: Areca nut (various doses)
Number of subjects: 23
Study 12519653 — intervention group
Group type: EXPERIMENTAL
Intervention: Areca nut (postprandial)
Number of subjects: 23
Study 12519653 — intervention group
Group type: EXPERIMENTAL
Intervention: Areca nut
Number of subjects: 23
Study 11769869 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater occipital nerve block (GON)
Number of subjects: 0
Study 11769869 — intervention group
Group type: EXPERIMENTAL
Intervention: C2/C3 nerve block
Number of subjects: 0
Study 9086386 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES + TED)
Number of subjects: 30
Study 9086386 — intervention group
Group type: COMPARATOR
Intervention: Sequential compression device (SCD + TED)
Number of subjects: 30
Study 9086386 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 8460756 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg (group 1)
Number of subjects: 94
Study 8460756 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg (group 2)
Number of subjects: 94
Study 8460756 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg + Metoclopramide 10 mg (group 3)
Number of subjects: 94
Study 8460756 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg + Metoclopramide 10 mg (group 4)
Number of subjects: 94
Study 3956895 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min daily bicycle exercise
Number of subjects: 13
Study 3956895 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising controls
Number of subjects: 13
Study 30859987 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 40mg
Number of subjects: 95
Study 30859987 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 80mg
Number of subjects: 95
Study 30202085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg every 3 weeks (Q3W) or 10 mg/kg Q2W or Q3W
Number of subjects: 84
Study 30202085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in ipilimumab-naive patients
Number of subjects: 84
Study 30202085 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in ipilimumab-treated patients
Number of subjects: 84
Study 27812149 — intervention group
Group type: COMPARATOR
Intervention: Acarbose
Number of subjects: 60
Study 27812149 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 60
Study 25095772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 grams taken one hour before exposure)
Number of subjects: 63
Study 25095772 — intervention group
Group type: COMPARATOR
Intervention: Placebo (taken one hour before exposure)
Number of subjects: 63
Study 23194486 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous diuretics
Number of subjects: 308
Study 23194486 — intervention group
Group type: COMPARATOR
Intervention: Bolus intravenous diuretics
Number of subjects: 308
Study 23194486 — intervention group
Group type: EXPERIMENTAL
Intervention: High initial intravenous diuretic dose
Number of subjects: 308
Study 23194486 — intervention group
Group type: COMPARATOR
Intervention: Low initial intravenous diuretic dose
Number of subjects: 308
Study 23194486 — intervention group
Group type: EXPERIMENTAL
Intervention: High outpatient diuretic doses
Number of subjects: 308
Study 23194486 — intervention group
Group type: COMPARATOR
Intervention: Low outpatient diuretic doses
Number of subjects: 308
Study 23194486 — intervention group
Group type: EXPERIMENTAL
Intervention: Mode of therapy (bolus vs continuous)
Number of subjects: 308
Study 20413082 — intervention group
Group type: EXPERIMENTAL
Intervention: Activ-O-Meter (internet-based computer-tailored physical activity intervention)
Number of subjects: 675
Study 20413082 — intervention group
Group type: COMPARATOR
Intervention: Generic standard advice (control)
Number of subjects: 675
Study 18640939 — intervention group
Group type: EXPERIMENTAL
Intervention: C8092A C/A or A/A genotypes
Number of subjects: 233
Study 18640939 — intervention group
Group type: COMPARATOR
Intervention: C/C genotype
Number of subjects: 233
Study 18640939 — intervention group
Group type: EXPERIMENTAL
Intervention: Codon 118 polymorphism
Number of subjects: 233
Study 15845553 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of noise hazard (93%)
Number of subjects: 116
Study 15845553 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of prevention methods (92%)
Number of subjects: 116
Study 15845553 — intervention group
Group type: EXPERIMENTAL
Intervention: Possession of hearing protectors (27%)
Number of subjects: 116
Study 15845553 — intervention group
Group type: EXPERIMENTAL
Intervention: Usage of hearing protectors (28%)
Number of subjects: 116
Study 11171733 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (300 microg) administered IV daily for up to 5 days
Number of subjects: 18
Study 11171733 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered IV daily for up to 5 days
Number of subjects: 18
Study 9665023 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 30
Study 9665023 — intervention group
Group type: COMPARATOR
Intervention: 5% solution of glucose (Control)
Number of subjects: 30
Study 8144338 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet conditions for group A readers (accustomed to quiet environment)
Number of subjects: 120
Study 8144338 — intervention group
Group type: COMPARATOR
Intervention: Noisy conditions for group A readers (accustomed to quiet environment)
Number of subjects: 120
Study 8144338 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet conditions for group B readers (accustomed to noisy environments)
Number of subjects: 120
Study 8144338 — intervention group
Group type: COMPARATOR
Intervention: Noisy conditions for group B readers (accustomed to noisy environments)
Number of subjects: 120
Study 3276282 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 119
Study 3276282 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 119
Study 3276282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 1581424 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-212
Number of subjects: 23
Study 1581424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 66167 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune serum globulin preoperatively
Number of subjects: 44
Study 66167 — intervention group
Group type: COMPARATOR
Intervention: Albumin placebo
Number of subjects: 44
Study 31994271 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Number of subjects: 0
Study 31994271 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF chemotherapy and PI3K-AKT-mTOR inhibitors
Number of subjects: 0
Study 31994271 — intervention group
Group type: COMPARATOR
Intervention: High stathmin expression
Number of subjects: 0
Study 30660818 — intervention group
Group type: EXPERIMENTAL
Intervention: Whipple accelerated recovery pathway (WARP)
Number of subjects: 76
Study 30660818 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional 7-day pathway)
Number of subjects: 76
Study 26456628 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded BFR (n = 16)
Number of subjects: 43
Study 26456628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonblinded BFR (n = 13)
Number of subjects: 43
Study 26456628 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 43
Study 26456628 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded BFR vs Nonblinded BFR
Number of subjects: 43
Study 25784079 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily meditation for six weeks (treatment group)
Number of subjects: 27
Study 25784079 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 27
Study 24081232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 3899
Study 24081232 — intervention group
Group type: COMPARATOR
Intervention: Control group (diabetes support and education)
Number of subjects: 3899
Study 21619828 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg simvastatin, taken in evening for 4 months
Number of subjects: 96
Study 21619828 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg warfarin, once a day for 4 months
Number of subjects: 96
Study 19821135 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation
Number of subjects: 163
Study 19821135 — intervention group
Group type: COMPARATOR
Intervention: Inpatient rehabilitation
Number of subjects: 163
Study 16753449 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b (5 x 10(6) U) biweekly for 12 weeks
Number of subjects: 117
Study 16753449 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 10 ml) biweekly for 12 weeks
Number of subjects: 117
Study 16753449 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b
Number of subjects: 117
Study 16753449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 15912723 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar event
Number of subjects: 0
Study 15912723 — intervention group
Group type: COMPARATOR
Intervention: Unfamiliar event
Number of subjects: 0
Study 11487170 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium, chromium:YSGG laser irradiation with water spray cooling
Number of subjects: 60
Study 11487170 — intervention group
Group type: COMPARATOR
Intervention: Erbium, chromium:YSGG laser irradiation without cooling
Number of subjects: 60
Study 11487170 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium, chromium:YSGG laser irradiation with cooling
Number of subjects: 60